|
Variable
|
TNFi trough serum levels
|
p value
|
|---|
|
β coefficient (95% CI)
|
|---|
|
DAS28-ESR
|
0.26 (0.068–0.004)
|
0.001
|
|
Reduced dose (yes/no)
|
0.022 (0.168–0.012)
|
0.271
|
|
Diagnosis (RA/PsA)
|
0.005 (0.058–0.144)
|
0.662
|
|
Monotherapy (yes/no)
|
0.0004 (0.090–0.062)
|
0.863
|
|
Follow-up
|
|
Baseline
|
1
| |
|
4-month visit
|
0.012 (0.044–0.0004)
|
0.023
|
|
8-month visit
|
0.004 (0.032–0.002)
|
0.280
|
|
12-month visit
|
0.002 (0.005–0.032)
|
0.409
|
|
Steroids
|
0.020 (0.325–0.090)
|
0.538
|
|
Constant
|
4.45 (2.99 to 6.25)
|
< 0.0001
|
- Significant values are shown in bold typeface
- CI confidence interval, DAS28-ESR 28-joint Disease Activity Score-erythrocyte sedimentation rate, GEE generalized estimating equation, PsA psoriatic arthritis, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitors
